{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-281581","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.674311+00:00","generated_at":"2026-05-16T19:54:34.637657+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"confidence":"high","headline":"Sensei discontinues solnerstotug, starts strategic review; workforce cut 65%","bullets":["Discontinued solnerstotug development; Board considering sale, merger, or wind-down.","Workforce cut ~65% to preserve cash; small team retained for strategic review.","Cash $25.0M as of Sep 30, 2025, down from $41.3M at Dec 31, 2024.","Q3 2025 net loss $4.6M (vs $7.3M YoY); R&D $2.5M (vs $4.6M YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-281581","json":"https://secwatch.observer/filing/0001193125-25-281581.json","markdown":"https://secwatch.observer/filing/0001193125-25-281581.md","text":"https://secwatch.observer/filing/0001193125-25-281581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/0001193125-25-281581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:54:34.637657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}